US5994392A
(en)
|
1988-02-26 |
1999-11-30 |
Neuromedica, Inc. |
Antipsychotic prodrugs comprising an antipsychotic agent coupled to an unsaturated fatty acid
|
US5268164A
(en)
*
|
1990-04-23 |
1993-12-07 |
Alkermes, Inc. |
Increasing blood-brain barrier permeability with permeabilizer peptides
|
US5545719A
(en)
*
|
1990-05-01 |
1996-08-13 |
Neuromedica, Inc. |
Nerve growth peptides
|
US5439884A
(en)
*
|
1992-07-27 |
1995-08-08 |
Oregon Regional Primate Research Center |
Method of controlling fertilization using bombesin or its agonist
|
ATE220327T1
(de)
*
|
1992-09-29 |
2002-07-15 |
Inhale Therapeutic Syst |
Pulmonale abgabe von aktiven fragmenten des parathormons
|
US5434137A
(en)
*
|
1993-05-10 |
1995-07-18 |
Black; Keith L. |
Method for selective opening of abnormal brain tissue capillaries
|
AU1947395A
(en)
*
|
1994-02-28 |
1995-09-11 |
Medinova Medical Consulting Gmbh |
Drug targeting system, method for preparing same and its use
|
US20030113273A1
(en)
*
|
1996-06-17 |
2003-06-19 |
Patton John S. |
Methods and compositions for pulmonary delivery of insulin
|
US5962477A
(en)
*
|
1994-04-12 |
1999-10-05 |
Adolor Corporation |
Screening methods for cytokine inhibitors
|
US6190691B1
(en)
|
1994-04-12 |
2001-02-20 |
Adolor Corporation |
Methods for treating inflammatory conditions
|
GB2288732B
(en)
*
|
1994-04-13 |
1998-04-29 |
Quadrant Holdings Cambridge |
Pharmaceutical compositions
|
US5585355A
(en)
*
|
1994-04-22 |
1996-12-17 |
Alkermes, Inc. |
Method for increasing blood-ocular barrier permeability with permeabilizer peptides
|
ATE299892T1
(de)
*
|
1994-05-18 |
2005-08-15 |
Nektar Therapeutics |
Methoden und zusammensetzungen für die trockenpuderarznei aus interferonen
|
US6290991B1
(en)
*
|
1994-12-02 |
2001-09-18 |
Quandrant Holdings Cambridge Limited |
Solid dose delivery vehicle and methods of making same
|
US5849761A
(en)
*
|
1995-09-12 |
1998-12-15 |
Regents Of The University Of California |
Peripherally active anti-hyperalgesic opiates
|
US6573282B1
(en)
|
1995-09-12 |
2003-06-03 |
Adolor Corporation |
Peripherally active anti-hyperalgesic opiates
|
WO1997041856A1
(en)
*
|
1996-05-08 |
1997-11-13 |
Massachusetts Institute Of Technology |
ORGANOMETALLIC LIGANDS FOR THE LOCALIZATION AND QUANTIFICATION OF AMYLOID IN VIVO AND $i(IN VITRO)
|
US6576636B2
(en)
|
1996-05-22 |
2003-06-10 |
Protarga, Inc. |
Method of treating a liver disorder with fatty acid-antiviral agent conjugates
|
US5795909A
(en)
|
1996-05-22 |
1998-08-18 |
Neuromedica, Inc. |
DHA-pharmaceutical agent conjugates of taxanes
|
US5752515A
(en)
*
|
1996-08-21 |
1998-05-19 |
Brigham & Women's Hospital |
Methods and apparatus for image-guided ultrasound delivery of compounds through the blood-brain barrier
|
WO1998030229A1
(en)
|
1997-01-10 |
1998-07-16 |
Massachusetts Institute Of Technology |
TREATMENTS FOR NEUROTOXICITY IN ALZHEIMER'S DISEASE BY β-AMYLOID PEPTIDES
|
US6942963B1
(en)
|
1997-01-10 |
2005-09-13 |
Massachusetts Institute Of Technology |
Methods for identifying treatments for neurotoxicity in Alzheimer's disease caused by β-amyloid peptides
|
US20030035778A1
(en)
*
|
1997-07-14 |
2003-02-20 |
Robert Platz |
Methods and compositions for the dry powder formulation of interferon
|
US6309623B1
(en)
*
|
1997-09-29 |
2001-10-30 |
Inhale Therapeutic Systems, Inc. |
Stabilized preparations for use in metered dose inhalers
|
US6565885B1
(en)
|
1997-09-29 |
2003-05-20 |
Inhale Therapeutic Systems, Inc. |
Methods of spray drying pharmaceutical compositions
|
US20060165606A1
(en)
|
1997-09-29 |
2006-07-27 |
Nektar Therapeutics |
Pulmonary delivery particles comprising water insoluble or crystalline active agents
|
US6225444B1
(en)
|
1998-02-10 |
2001-05-01 |
Protarga, Inc. |
Neuroprotective peptides and uses thereof
|
WO2000037616A1
(en)
*
|
1998-12-23 |
2000-06-29 |
Cytoscan Sciences L.L.C. |
Compounds, methods of screening and methods of treatment for central and peripheral nervous system disorders
|
US6630120B1
(en)
|
1999-03-08 |
2003-10-07 |
Alkermes, Inc. |
Agents to increase the uptake of pharmaceuticals and diagnostic substances into solid tumors
|
US7235583B1
(en)
*
|
1999-03-09 |
2007-06-26 |
Luitpold Pharmaceuticals, Inc., |
Fatty acid-anticancer conjugates and uses thereof
|
US6774119B1
(en)
*
|
1999-04-26 |
2004-08-10 |
Cedars-Sinai Medical Center |
Herpes simplex virus type 1 (hsv-1)-derived vector for selectively inhibiting malignant cells and methods for its use to treat cancers and to express desired traits in malignant and non-malignant mammalian cells
|
MXPA02003176A
(es)
|
1999-10-04 |
2002-09-30 |
Shearwater Corp |
Neuropeptidos estabilizados por polimero.
|
US20050153940A1
(en)
*
|
2000-01-26 |
2005-07-14 |
Cedars-Sinai Medical Center |
Method for using potassium channel activation for delivering a medicant to an abnormal brain region and/or a malignant tumor
|
US7018979B1
(en)
|
2000-01-26 |
2006-03-28 |
Cedars-Sinai Medical Center |
Method for using potassium channel agonists for delivering a medicant to an abnormal brain region and/or a malignant tumor
|
EP1251840A2
(de)
*
|
2000-01-26 |
2002-10-30 |
Cedars-Sinai Medical Center |
Verwendung von kaliumkanalaktivatoren zur verabreichung von medikamenten an anormalen gehirnregionen und/oder bösartigen tumoren
|
US7235397B1
(en)
*
|
2000-04-14 |
2007-06-26 |
Gensys, Inc. |
Methods and compositions for culturing spirochete and treating spirochetal diseases
|
CA2382133C
(en)
|
2000-05-10 |
2010-11-23 |
Alliance Pharmaceutical Corporation |
Phospholipid-based powders for drug delivery
|
US7871598B1
(en)
|
2000-05-10 |
2011-01-18 |
Novartis Ag |
Stable metal ion-lipid powdered pharmaceutical compositions for drug delivery and methods of use
|
US8404217B2
(en)
|
2000-05-10 |
2013-03-26 |
Novartis Ag |
Formulation for pulmonary administration of antifungal agents, and associated methods of manufacture and use
|
US8251986B2
(en)
|
2000-08-17 |
2012-08-28 |
Angiodynamics, Inc. |
Method of destroying tissue cells by eletroporation
|
WO2002035987A2
(en)
*
|
2000-11-03 |
2002-05-10 |
Massachusetts Institute Of Technology |
METHODS FOR IDENTIFYING TREATMENTS FOR NEUROTOXICITY IN ALZHEIMER'S DISEASE CAUSED BY β-AMYLOID PEPTIDES
|
US7067550B2
(en)
*
|
2000-11-03 |
2006-06-27 |
Massachusetts Institute Of Technology |
Treatments for neurotoxicity in Alzheimer's Disease
|
JP2005500988A
(ja)
*
|
2001-03-23 |
2005-01-13 |
ルイトポルド・ファーマシューティカルズ・インコーポレーテッド |
脂肪族アミン薬物複合体
|
ATE556706T1
(de)
*
|
2001-03-23 |
2012-05-15 |
Luitpold Pharm Inc |
Fettalkohol-arzneimittel-konjugate
|
US7211561B2
(en)
*
|
2001-10-12 |
2007-05-01 |
Cedars-Sinai Medical Center |
Method for inducing selective cell death of malignant cells by activation of calcium-activated potassium channels (KCa)
|
ES2364636T3
(es)
|
2001-12-19 |
2011-09-08 |
Novartis Ag |
Administración pulmonar de aminoglucósidos.
|
WO2004069857A2
(en)
*
|
2003-02-06 |
2004-08-19 |
Uutech Limited |
“peptides, compositions and uses thereof”
|
US7485706B2
(en)
*
|
2003-07-30 |
2009-02-03 |
The Board Of Trustees Of The Leland Stanford Junior University |
Neurodegenerative protein aggregation inhibition methods and compounds
|
US20070293539A1
(en)
*
|
2004-03-18 |
2007-12-20 |
Lansbury Peter T |
Methods for the treatment of synucleinopathies
|
US20050272068A1
(en)
*
|
2004-03-18 |
2005-12-08 |
The Brigham And Women's Hospital, Inc. |
UCH-L1 expression and cancer therapy
|
JP2007538004A
(ja)
*
|
2004-03-18 |
2007-12-27 |
ザ ブライハム アンド ウイメンズ ホスピタル, インコーポレイテッド |
シヌクレイノパチーを治療する方法
|
US20050272722A1
(en)
*
|
2004-03-18 |
2005-12-08 |
The Brigham And Women's Hospital, Inc. |
Methods for the treatment of synucleinopathies
|
US20050288298A1
(en)
*
|
2004-03-18 |
2005-12-29 |
The Brigham And Women's Hospital, Inc. |
Methods for the treatment of synucleinopathies
|
US20050277629A1
(en)
*
|
2004-03-18 |
2005-12-15 |
The Brigham And Women's Hospital, Inc. |
Methods for the treatment of synucleinopathies (Lansbury)
|
US20060111307A1
(en)
*
|
2004-11-16 |
2006-05-25 |
Wendye Robbins |
Methods and compositions for treating pain
|
US20070087977A1
(en)
*
|
2004-11-16 |
2007-04-19 |
Wendye Robbins |
Methods and compositions for treating pain
|
US20060194821A1
(en)
*
|
2005-02-18 |
2006-08-31 |
The Brigham And Women's Hospital, Inc. |
Compounds inhibiting the aggregation of superoxide dismutase-1
|
US20080188480A1
(en)
*
|
2005-02-22 |
2008-08-07 |
Cedars-Sinai Medical Center |
Use of Sildenafil, Vardenafil and Other 5-Phosphodiesterase Inhibitors to Enhance Permeability of the Abnormal Blood-Brain Barrier
|
EP1957093B1
(de)
|
2005-08-29 |
2017-04-12 |
SHASHOUA, Victor E. |
Neuroprotektive und neurorestorative verfahren und zusammensetzungen
|
EP2325208B1
(de)
|
2005-12-15 |
2017-09-20 |
Genentech, Inc. |
Polyubiqutin Antikörper
|
EP1968591A4
(de)
|
2005-12-23 |
2010-02-17 |
Link Medicine Corp |
Behandlung von synucleinopathien
|
WO2007131034A1
(en)
*
|
2006-05-03 |
2007-11-15 |
The Regents Of The University Of Michigan |
Pyrimidone derivatives which are modulators of heat shock protein (hsp) 70
|
JP2009536526A
(ja)
|
2006-05-04 |
2009-10-15 |
ジェネンテック・インコーポレーテッド |
Zpaポリペプチドに関連する方法および組成物
|
RS53160B
(en)
|
2006-07-14 |
2014-06-30 |
Ac Immune S.A. |
HUMANIZED BETA AMILOID ANTIBODY
|
PL2468770T3
(pl)
|
2006-07-14 |
2018-07-31 |
Ac Immune S.A. |
Humanizowane przeciwciało przeciw amyloidowi beta
|
US7960139B2
(en)
|
2007-03-23 |
2011-06-14 |
Academia Sinica |
Alkynyl sugar analogs for the labeling and visualization of glycoconjugates in cells
|
KR101600095B1
(ko)
|
2007-06-12 |
2016-03-07 |
에이씨 이뮨 에스.에이. |
모노클로널 항 베타 아밀로이드 항체
|
SG182192A1
(en)
|
2007-06-12 |
2012-07-30 |
Ac Immune Sa |
Humanized antibodies to amyloid beta
|
US20100297012A1
(en)
|
2007-10-05 |
2010-11-25 |
Andrea Pfeifer |
Humanized antibody
|
TWI580694B
(zh)
|
2007-11-30 |
2017-05-01 |
建南德克公司 |
抗-vegf抗體
|
US8232402B2
(en)
*
|
2008-03-12 |
2012-07-31 |
Link Medicine Corporation |
Quinolinone farnesyl transferase inhibitors for the treatment of synucleinopathies and other indications
|
AU2009243079A1
(en)
|
2008-04-29 |
2009-11-05 |
Virginia Tech Intellectual Properties, Inc. |
Irreversible electroporation to create tissue scaffolds
|
US10702326B2
(en)
|
2011-07-15 |
2020-07-07 |
Virginia Tech Intellectual Properties, Inc. |
Device and method for electroporation based treatment of stenosis of a tubular body part
|
US10117707B2
(en)
|
2008-04-29 |
2018-11-06 |
Virginia Tech Intellectual Properties, Inc. |
System and method for estimating tissue heating of a target ablation zone for electrical-energy based therapies
|
US10272178B2
(en)
|
2008-04-29 |
2019-04-30 |
Virginia Tech Intellectual Properties Inc. |
Methods for blood-brain barrier disruption using electrical energy
|
US9198733B2
(en)
|
2008-04-29 |
2015-12-01 |
Virginia Tech Intellectual Properties, Inc. |
Treatment planning for electroporation-based therapies
|
US11272979B2
(en)
|
2008-04-29 |
2022-03-15 |
Virginia Tech Intellectual Properties, Inc. |
System and method for estimating tissue heating of a target ablation zone for electrical-energy based therapies
|
US9867652B2
(en)
|
2008-04-29 |
2018-01-16 |
Virginia Tech Intellectual Properties, Inc. |
Irreversible electroporation using tissue vasculature to treat aberrant cell masses or create tissue scaffolds
|
US10448989B2
(en)
|
2009-04-09 |
2019-10-22 |
Virginia Tech Intellectual Properties, Inc. |
High-frequency electroporation for cancer therapy
|
US10238447B2
(en)
|
2008-04-29 |
2019-03-26 |
Virginia Tech Intellectual Properties, Inc. |
System and method for ablating a tissue site by electroporation with real-time monitoring of treatment progress
|
US9283051B2
(en)
|
2008-04-29 |
2016-03-15 |
Virginia Tech Intellectual Properties, Inc. |
System and method for estimating a treatment volume for administering electrical-energy based therapies
|
US11254926B2
(en)
|
2008-04-29 |
2022-02-22 |
Virginia Tech Intellectual Properties, Inc. |
Devices and methods for high frequency electroporation
|
US8992517B2
(en)
|
2008-04-29 |
2015-03-31 |
Virginia Tech Intellectual Properties Inc. |
Irreversible electroporation to treat aberrant cell masses
|
US10245098B2
(en)
|
2008-04-29 |
2019-04-02 |
Virginia Tech Intellectual Properties, Inc. |
Acute blood-brain barrier disruption using electrical energy based therapy
|
US8680020B2
(en)
|
2008-07-15 |
2014-03-25 |
Academia Sinica |
Glycan arrays on PTFE-like aluminum coated glass slides and related methods
|
CN102245208B
(zh)
|
2008-10-14 |
2016-03-16 |
霍夫曼-拉罗奇有限公司 |
免疫球蛋白变体及其用途
|
CN104689316A
(zh)
|
2008-10-22 |
2015-06-10 |
弗·哈夫曼-拉罗切有限公司 |
轴突变性的调节
|
US20100331363A1
(en)
*
|
2008-11-13 |
2010-12-30 |
Link Medicine Corporation |
Treatment of mitochondrial disorders using a farnesyl transferase inhibitor
|
MX2011005096A
(es)
*
|
2008-11-13 |
2011-11-18 |
Link Medicine Corp |
Derivados de azaquinolinona y usos de los mismos.
|
US20110060005A1
(en)
*
|
2008-11-13 |
2011-03-10 |
Link Medicine Corporation |
Treatment of mitochondrial disorders using a farnesyl transferase inhibitor
|
AU2009318098B2
(en)
|
2008-11-20 |
2015-07-16 |
Northwestern University |
Treatment of amyotrophic lateral sclerosis
|
JP6039183B2
(ja)
|
2008-12-23 |
2016-12-07 |
ジェネンテック, インコーポレイテッド |
プロテインaに対する結合が変化した免疫グロブリン変異体
|
US20100189800A1
(en)
*
|
2009-01-23 |
2010-07-29 |
Peter Markland |
Continous double emulsion process for making microparticles
|
US11382681B2
(en)
|
2009-04-09 |
2022-07-12 |
Virginia Tech Intellectual Properties, Inc. |
Device and methods for delivery of high frequency electrical pulses for non-thermal ablation
|
US11638603B2
(en)
|
2009-04-09 |
2023-05-02 |
Virginia Tech Intellectual Properties, Inc. |
Selective modulation of intracellular effects of cells using pulsed electric fields
|
WO2010129665A2
(en)
|
2009-05-05 |
2010-11-11 |
Cambria Pharmaceuticals, Inc. |
Pyrimidine-2,4,6-triones for use in the treatment of amyotrophic lateral sclerosis
|
US8903488B2
(en)
|
2009-05-28 |
2014-12-02 |
Angiodynamics, Inc. |
System and method for synchronizing energy delivery to the cardiac rhythm
|
MX2011013016A
(es)
|
2009-06-05 |
2012-04-20 |
Link Medicine Corp |
Derivados de aminopirrolidinona y usos de los mismos.
|
US9895189B2
(en)
|
2009-06-19 |
2018-02-20 |
Angiodynamics, Inc. |
Methods of sterilization and treating infection using irreversible electroporation
|
AU2010289400B2
(en)
|
2009-09-02 |
2014-10-23 |
Curis, Inc. |
Mutant smoothened and methods of using the same
|
AU2010310589A1
(en)
|
2009-10-22 |
2012-05-10 |
Genentech, Inc. |
Modulation of axon degeneration
|
US11377485B2
(en)
|
2009-12-02 |
2022-07-05 |
Academia Sinica |
Methods for modifying human antibodies by glycan engineering
|
US10087236B2
(en)
|
2009-12-02 |
2018-10-02 |
Academia Sinica |
Methods for modifying human antibodies by glycan engineering
|
JP2013513588A
(ja)
|
2009-12-11 |
2013-04-22 |
ジーンコード エーエス |
Gdnfファミリーリガンド(gfl)のミメティックまたはretシグナル経路活性化因子を用いた、神経系細胞の生存を容易にするための方法
|
TWI505836B
(zh)
|
2009-12-11 |
2015-11-01 |
Genentech Inc |
抗-vegf-c抗體及其使用方法
|
MX2012007379A
(es)
|
2009-12-23 |
2012-08-31 |
Genentech Inc |
Anticuerpos anti-bv8 y usos de los mismos.
|
WO2011130332A1
(en)
|
2010-04-12 |
2011-10-20 |
Academia Sinica |
Glycan arrays for high throughput screening of viruses
|
JP5947289B2
(ja)
|
2010-05-10 |
2016-07-06 |
アカデミア シニカAcademia Sinica |
抗インフルエンザ活性を有するザナミビルホスホネート同族体およびインフルエンザウイルスのオセルタミビルに対する感受性の決定
|
BR112013002297A2
(pt)
|
2010-07-30 |
2016-05-24 |
Ac Immune Sa |
anticorpos humanizados seguros e funcionais
|
EP3527220A1
(de)
|
2010-08-12 |
2019-08-21 |
AC Immune S.A. |
Manipulation von impfstoffen
|
WO2012047968A2
(en)
|
2010-10-05 |
2012-04-12 |
Genentech, Inc. |
Mutant smoothened and methods of using the same
|
WO2012045882A2
(en)
|
2010-10-07 |
2012-04-12 |
Ac Immune S.A. |
Pharmaceutical composition
|
US9700368B2
(en)
|
2010-10-13 |
2017-07-11 |
Angiodynamics, Inc. |
System and method for electrically ablating tissue of a patient
|
EP2632434A1
(de)
|
2010-10-26 |
2013-09-04 |
AC Immune S.A. |
Konstrukt auf liposomenbasis mit einem anhand von hydrophoben einheiten modifizierten peptid
|
EP2638070B1
(de)
|
2010-11-10 |
2016-10-19 |
F.Hoffmann-La Roche Ag |
Verfahren und zusammensetzungen zur immuntherapie bei nervenerkrankungen
|
WO2012177997A1
(en)
|
2011-06-22 |
2012-12-27 |
The General Hospital Corporation |
Treatment of proteinopathies
|
US9078665B2
(en)
|
2011-09-28 |
2015-07-14 |
Angiodynamics, Inc. |
Multiple treatment zone ablation probe
|
CA2850686C
(en)
|
2011-10-07 |
2020-09-08 |
Ac Immune S.A. |
Phosphospecific antibodies recognising tau
|
WO2013056054A2
(en)
|
2011-10-14 |
2013-04-18 |
Genentech, Inc |
Peptide inhibitors of bace1
|
RU2014123511A
(ru)
|
2011-11-10 |
2015-12-20 |
Дженентек, Инк |
Способы лечения, диагностики и мониторинга болезни альцгеймера
|
EP2830643A1
(de)
|
2012-03-26 |
2015-02-04 |
INSERM - Institut National de la Santé et de la Recherche Médicale |
Verfahren und pharmazeutische zusammensetzungen zur prävention oder behandlung eines ischämiebedingten organschadens
|
MX356800B
(es)
|
2012-04-05 |
2018-06-13 |
Ac Immune Sa |
Anticuerpo tau humanizado.
|
US10130714B2
(en)
|
2012-04-14 |
2018-11-20 |
Academia Sinica |
Enhanced anti-influenza agents conjugated with anti-inflammatory activity
|
JP6267193B2
(ja)
|
2012-05-22 |
2018-01-24 |
エフ.ホフマン−ラ ロシュ アーゲーF. Hoffmann−La Roche Aktiengesellschaft |
置換ジピリジルアミン類及びそれらの使用
|
SG11201408284VA
(en)
|
2012-05-22 |
2015-02-27 |
Xenon Pharmaceuticals Inc |
N-substituted benzamides and their use in the treatment of pain
|
EP2870138B1
(de)
|
2012-07-06 |
2018-08-22 |
Genentech, Inc. |
N-substituierte benzamide und verfahren zur verwendung davon
|
JP6302909B2
(ja)
|
2012-08-18 |
2018-03-28 |
アカデミア シニカAcademia Sinica |
シアリダーゼの同定および画像化のための細胞透過性プローブ
|
AU2013305827A1
(en)
|
2012-08-21 |
2015-03-05 |
Academia Sinica |
Benzocyclooctyne compounds and uses thereof
|
WO2014049047A1
(en)
|
2012-09-27 |
2014-04-03 |
F. Hoffmann-La Roche Ag |
Substituted sulfonamide compounds
|
AU2013204200B2
(en)
|
2012-10-11 |
2016-10-20 |
Brandeis University |
Treatment of amyotrophic lateral sclerosis
|
EP2945938B1
(de)
|
2013-01-18 |
2018-03-07 |
F. Hoffmann-La Roche AG |
3-substituierte pyrazole und verwendung als dlk-hemmer
|
US9888956B2
(en)
|
2013-01-22 |
2018-02-13 |
Angiodynamics, Inc. |
Integrated pump and generator device and method of use
|
CN105263490B
(zh)
|
2013-03-14 |
2018-05-22 |
基因泰克公司 |
取代的三唑并吡啶及其使用方法
|
WO2014150877A2
(en)
|
2013-03-15 |
2014-09-25 |
Ac Immune S.A. |
Anti-tau antibodies and methods of use
|
CN105164114B
(zh)
|
2013-05-01 |
2018-03-23 |
豪夫迈·罗氏有限公司 |
C‑连接的杂环烷基取代的嘧啶类和它们的用途
|
EA029568B8
(ru)
|
2013-05-01 |
2018-08-31 |
Ф.Хоффманн-Ля Рош Аг |
Бигетероарильные соединения и их применения
|
WO2014210397A1
(en)
|
2013-06-26 |
2014-12-31 |
Academia Sinica |
Rm2 antigens and use thereof
|
US9981030B2
(en)
|
2013-06-27 |
2018-05-29 |
Academia Sinica |
Glycan conjugates and use thereof
|
CN105682666B
(zh)
|
2013-09-06 |
2021-06-01 |
中央研究院 |
使用醣脂激活人类iNKT细胞
|
DK3055302T3
(en)
|
2013-10-11 |
2019-03-18 |
Hoffmann La Roche |
Substituted heterocyclic sulfonamide compounds useful as TRPA1 modulators
|
MX2016008110A
(es)
|
2013-12-20 |
2016-08-19 |
Hoffmann La Roche |
Derivados de pirazol como inhibidores de la cinasa de cremallera de leucina dual (dlk) y usos de los mismos.
|
WO2016114819A1
(en)
|
2015-01-16 |
2016-07-21 |
Academia Sinica |
Compositions and methods for treatment and detection of cancers
|
US10150818B2
(en)
|
2014-01-16 |
2018-12-11 |
Academia Sinica |
Compositions and methods for treatment and detection of cancers
|
EP3094352B1
(de)
|
2014-01-16 |
2020-09-23 |
Academia Sinica |
Zusammensetzungen und verfahren zur behandlung und zum nachweis von krebs
|
JP2017506884A
(ja)
*
|
2014-01-17 |
2017-03-16 |
ウェイク・フォレスト・ユニヴァーシティ・ヘルス・サイエンシズ |
活性薬の送達を増強するための方法
|
JP6736467B2
(ja)
|
2014-02-04 |
2020-08-05 |
ジェネンテック, インコーポレイテッド |
平滑化変異体及びその使用方法
|
EP3129767B1
(de)
|
2014-03-27 |
2021-09-01 |
Academia Sinica |
Reaktive markierungsverbindungen und ihre verwendungen
|
US10471254B2
(en)
|
2014-05-12 |
2019-11-12 |
Virginia Tech Intellectual Properties, Inc. |
Selective modulation of intracellular effects of cells using pulsed electric fields
|
TWI679020B
(zh)
|
2014-05-27 |
2019-12-11 |
中央研究院 |
抗her2醣抗體及其用途
|
KR20170003720A
(ko)
|
2014-05-27 |
2017-01-09 |
아카데미아 시니카 |
항-cd20 글리코항체 및 이의 용도
|
TWI717319B
(zh)
|
2014-05-27 |
2021-02-01 |
中央研究院 |
得自類桿菌屬之岩藻糖苷酶及其用途
|
US10118969B2
(en)
|
2014-05-27 |
2018-11-06 |
Academia Sinica |
Compositions and methods relating to universal glycoforms for enhanced antibody efficacy
|
KR102494193B1
(ko)
|
2014-05-28 |
2023-01-31 |
아카데미아 시니카 |
항-tnf-알파 글리코항체 및 이의 용도
|
CN106715418A
(zh)
|
2014-07-07 |
2017-05-24 |
基因泰克公司 |
治疗化合物及其使用方法
|
CN107001404B
(zh)
|
2014-09-08 |
2021-06-29 |
中央研究院 |
使用醣脂激活人类iNKT细胞
|
LT3221349T
(lt)
|
2014-11-19 |
2021-02-10 |
Axon Neuroscience Se |
Humanizuoti tau antikūnai, esant alzheimerio ligai
|
US10882920B2
(en)
|
2014-11-19 |
2021-01-05 |
Genentech, Inc. |
Antibodies against BACE1 and use thereof for neural disease immunotherapy
|
WO2016100325A1
(en)
|
2014-12-15 |
2016-06-23 |
Virginia Tech Intellectual Properties, Inc. |
Devices, systems, and methods for real-time monitoring of electrophysical effects during tissue treatment
|
US10495645B2
(en)
|
2015-01-16 |
2019-12-03 |
Academia Sinica |
Cancer markers and methods of use thereof
|
US9975965B2
(en)
|
2015-01-16 |
2018-05-22 |
Academia Sinica |
Compositions and methods for treatment and detection of cancers
|
JP6779887B2
(ja)
|
2015-01-24 |
2020-11-04 |
アカデミア シニカAcademia Sinica |
新規なグリカンコンジュゲートおよびその使用方法
|
CN107430127B
(zh)
|
2015-01-24 |
2020-08-28 |
中央研究院 |
癌症标记及其使用方法
|
KR102620346B1
(ko)
|
2015-01-30 |
2024-01-02 |
아카데미아 시니카 |
증진된 항체 효능을 위한 범용 당형태에 관한 조성물 및 방법
|
CA2975875A1
(en)
|
2015-02-04 |
2016-08-11 |
Genentech, Inc. |
Mutant smoothened and methods of using the same
|
CN107406462B
(zh)
|
2015-03-09 |
2020-11-10 |
豪夫迈·罗氏有限公司 |
三环dlk抑制剂及其用途
|
MA42118A
(fr)
|
2015-05-22 |
2018-03-28 |
Genentech Inc |
Benzamides substitués et leurs méthodes d'utilisation
|
JP2018526371A
(ja)
|
2015-08-27 |
2018-09-13 |
ジェネンテック, インコーポレイテッド |
治療化合物及びその使用方法
|
EP3344806A4
(de)
|
2015-09-04 |
2019-03-20 |
OBI Pharma, Inc. |
Glycanarrays und verfahren zur verwendung
|
EP3380466A1
(de)
|
2015-11-25 |
2018-10-03 |
Genentech, Inc. |
Substituierte benzamide als natriumkanalblocker
|
WO2017100623A1
(en)
|
2015-12-09 |
2017-06-15 |
Brandeis University |
Dbh inhibitors for treating or preventing memory loss
|
WO2017136558A1
(en)
|
2016-02-04 |
2017-08-10 |
Curis, Inc. |
Mutant smoothened and methods of using the same
|
CA3016170A1
(en)
|
2016-03-08 |
2017-09-14 |
Academia Sinica |
Methods for modular synthesis of n-glycans and arrays thereof
|
US10980894B2
(en)
|
2016-03-29 |
2021-04-20 |
Obi Pharma, Inc. |
Antibodies, pharmaceutical compositions and methods
|
CA3019560A1
(en)
|
2016-03-29 |
2017-10-05 |
Obi Pharma, Inc. |
Antibodies, pharmaceutical compositions and methods
|
EP3436432B1
(de)
|
2016-03-30 |
2021-01-27 |
Genentech, Inc. |
Substituierte benzamide und verfahren zur verwendung davon
|
KR20230110820A
(ko)
|
2016-04-22 |
2023-07-25 |
오비아이 파머 인코퍼레이티드 |
글로보 계열 항원을 통한 면역 활성화 또는 면역 조정에의한 암 면역요법
|
CN109476640B
(zh)
|
2016-07-20 |
2022-02-25 |
豪夫迈·罗氏有限公司 |
双环脯氨酸化合物
|
JP6975515B2
(ja)
|
2016-07-20 |
2021-12-01 |
エフ.ホフマン−ラ ロシュ アーゲーF. Hoffmann−La Roche Aktiengesellschaft |
Trpa1モデュレーターとしてのスルホニルシクロアルキルカルボキサミド化合物
|
EP3490592A4
(de)
|
2016-07-27 |
2020-03-25 |
OBI Pharma, Inc. |
Immunogene/therapeutische glycanzusammensetzungen und verwendungen davon
|
WO2018023121A1
(en)
|
2016-07-29 |
2018-02-01 |
Obi Pharma, Inc. |
Human antibodies, pharmaceutical compositions and methods
|
EP3497093B1
(de)
|
2016-08-12 |
2021-09-15 |
F. Hoffmann-La Roche AG |
Sulfonylpyridyl-trp-inhibitoren
|
JP7213549B2
(ja)
|
2016-08-22 |
2023-01-27 |
シーエイチオー ファーマ インコーポレイテッド |
抗体、結合性断片、および使用の方法
|
EP3526219B1
(de)
|
2016-10-17 |
2021-12-15 |
F. Hoffmann-La Roche AG |
Bicyclische pyridonlactame und verfahren zur verwendung davon
|
US10905492B2
(en)
|
2016-11-17 |
2021-02-02 |
Angiodynamics, Inc. |
Techniques for irreversible electroporation using a single-pole tine-style internal device communicating with an external surface electrode
|
EP3541414A4
(de)
|
2016-11-21 |
2020-11-11 |
OBI Pharma, Inc. |
Konjugierte biologische moleküle, pharmazeutische zusammensetzungen und verfahren
|
TW201831477A
(zh)
|
2016-11-28 |
2018-09-01 |
瑞士商赫孚孟拉羅股份公司 |
噁二唑酮瞬時受體電位通道抑制劑
|
WO2018100070A1
(en)
|
2016-12-02 |
2018-06-07 |
F. Hoffmann-La Roche Ag |
Bicyclic amide compounds and methods of use thereof
|
US11072607B2
(en)
|
2016-12-16 |
2021-07-27 |
Genentech, Inc. |
Inhibitors of RIP1 kinase and methods of use thereof
|
JP7178357B2
(ja)
|
2017-03-07 |
2022-11-25 |
エフ.ホフマン-ラ ロシュ アーゲー |
オキサジアゾール一過性受容器電位チャネル阻害剤
|
US10793550B2
(en)
|
2017-03-24 |
2020-10-06 |
Genentech, Inc. |
4-piperidin-n-(pyrimidin-4-yl)chroman-7-sulfonamide derivatives as sodium channel inhibitors
|
AU2018300043B2
(en)
|
2017-07-14 |
2021-04-01 |
F. Hoffmann-La Roche Ag |
Bicyclic ketone compounds and methods of use thereof
|
EP3460057A1
(de)
|
2017-09-22 |
2019-03-27 |
Max-Planck-Gesellschaft zur Förderung der Wissenschaften e.V. |
Kdac varianten und deren nutzung
|
CR20200151A
(es)
|
2017-10-11 |
2020-05-23 |
Hoffmann La Roche |
Compuestos bicíclicos y métodos de utilización de los mismos
|
WO2019086494A1
(en)
|
2017-10-31 |
2019-05-09 |
F. Hoffmann-La Roche Ag |
Bicyclic sulfones and sulfoxides and methods of use thereof
|
JP7235748B2
(ja)
|
2017-11-30 |
2023-03-08 |
ハンミ ファーム.カンパニー リミテッド |
4-アミノ-n-(1-((3-クロロ-2-フルオロフェニル)アミノ)-6-メチルイソキノリン-5-イル)チエノ[3,2-d]ピリミジン-7-カルボキサミドの塩とその結晶形態
|
US11607537B2
(en)
|
2017-12-05 |
2023-03-21 |
Virginia Tech Intellectual Properties, Inc. |
Method for treating neurological disorders, including tumors, with electroporation
|
CA3084985A1
(en)
|
2017-12-06 |
2019-06-13 |
Ovid Therapeutics Inc. |
Use of mir101 or mir128 in the treatment of seizure disorders
|
WO2019164778A1
(en)
|
2018-02-20 |
2019-08-29 |
Genentech, Inc. |
Process for preparing 1-arylsulfonyl-pyrrolidine-2-carboxamide transient receptor potential channel antagonist compounds and crystalline forms thereof
|
JP2021514980A
(ja)
|
2018-02-26 |
2021-06-17 |
ジェネンテック, インコーポレイテッド |
疼痛及び関連病態に対するピリジン−スルホンアミド化合物及びその使用
|
US11925405B2
(en)
|
2018-03-13 |
2024-03-12 |
Virginia Tech Intellectual Properties, Inc. |
Treatment planning system for immunotherapy enhancement via non-thermal ablation
|
US11311329B2
(en)
|
2018-03-13 |
2022-04-26 |
Virginia Tech Intellectual Properties, Inc. |
Treatment planning for immunotherapy based treatments using non-thermal ablation techniques
|
US10710994B2
(en)
|
2018-03-19 |
2020-07-14 |
Genentech, Inc. |
Oxadiazole transient receptor potential channel inhibitors
|
SG11202008098TA
(en)
|
2018-03-28 |
2020-10-29 |
Axon Neuroscience Se |
Antibody-based methods of detecting and treating alzheimer's disease
|
WO2019191702A1
(en)
|
2018-03-30 |
2019-10-03 |
F. Hoffmann-La Roche Ag |
Substituted hydro-pyrido-azines as sodium channel inhibitors
|
EP3781571B1
(de)
|
2018-04-20 |
2024-01-17 |
F. Hoffmann-La Roche AG |
N-[4-oxo-2,3-dihydro-pyrido[3,2-b][1,4]oxazepin-3-yl]-5,6-dihydro-4h-pyrrolo[1,2-b]pyrazol-2-carboxamid-derivate und ähnliche verbindungen als rip1 kinase inhibitoren zur behandlung von z.b. reizdarmsyndrom (rds)
|
TW202003490A
(zh)
|
2018-05-22 |
2020-01-16 |
瑞士商赫孚孟拉羅股份公司 |
治療性化合物及其使用方法
|
US11203645B2
(en)
|
2018-06-27 |
2021-12-21 |
Obi Pharma, Inc. |
Glycosynthase variants for glycoprotein engineering and methods of use
|
WO2020051099A1
(en)
|
2018-09-03 |
2020-03-12 |
Genentech, Inc. |
Carboxamide and sulfonamide derivatives useful as tead modulators
|
WO2020146615A1
(en)
|
2019-01-11 |
2020-07-16 |
Genentech, Inc. |
Bicyclic pyrrolotriazolr ketone compounds and methods of use thereof
|
US11950835B2
(en)
|
2019-06-28 |
2024-04-09 |
Virginia Tech Intellectual Properties, Inc. |
Cycled pulsing to mitigate thermal damage for multi-electrode irreversible electroporation therapy
|
CA3149729A1
(en)
|
2019-09-06 |
2021-03-11 |
Yan Chen |
Rip1 inhibitory compounds and methods for making and using the same
|
CN114761398A
(zh)
|
2019-09-06 |
2022-07-15 |
里格尔药品股份有限公司 |
杂环rip1激酶抑制剂
|
JP7395730B2
(ja)
|
2019-11-07 |
2023-12-11 |
ライジェル ファーマシューティカルズ, インコーポレイテッド |
ヘテロ環式rip1阻害化合物
|
CN114728905A
(zh)
|
2019-11-13 |
2022-07-08 |
基因泰克公司 |
治疗性化合物及使用方法
|
WO2021110995A1
(en)
|
2019-12-04 |
2021-06-10 |
Ac Immune Sa |
Novel molecules for therapy and diagnosis
|
US11787775B2
(en)
|
2020-07-24 |
2023-10-17 |
Genentech, Inc. |
Therapeutic compounds and methods of use
|
JP2023537761A
(ja)
|
2020-08-14 |
2023-09-05 |
エイシー イミューン ソシエテ アノニム |
ヒト化抗tdp-43結合分子およびその使用
|
BR112023005853A2
(pt)
|
2020-10-02 |
2023-05-02 |
Genentech Inc |
Processo para preparar um composto de fórmula i, compostos, processos para preparar o composto 1, forma cristalina, composição farmacêutica, processo de preparação da forma cristalina do composto i e método para tratar uma condição neurodegenerativa
|
EP4229082A1
(de)
|
2020-10-16 |
2023-08-23 |
AC Immune SA |
Alpha-synuclein bindende antikörper zur therapie und diagnose
|
AR125587A1
(es)
|
2021-03-11 |
2023-08-02 |
Rigel Pharmaceuticals Inc |
Inhibidores heterocíclicos de la quinasa de rip1
|
WO2023028056A1
(en)
|
2021-08-24 |
2023-03-02 |
Genentech, Inc. |
3-amino piperidyl sodium channel inhibitors
|
WO2023028077A1
(en)
|
2021-08-24 |
2023-03-02 |
Genentech, Inc. |
Sodium channel inhibitors and methods of designing same
|
TW202332429A
(zh)
|
2021-11-24 |
2023-08-16 |
美商建南德克公司 |
治療性化合物及其使用方法
|
US20230203062A1
(en)
|
2021-11-24 |
2023-06-29 |
Genentech, Inc. |
Therapeutic compounds and methods of use
|
TW202342519A
(zh)
|
2022-02-16 |
2023-11-01 |
瑞士商Ac 免疫有限公司 |
人源化抗tdp-43結合分子及其用途
|
WO2023194565A1
(en)
|
2022-04-08 |
2023-10-12 |
Ac Immune Sa |
Anti-tdp-43 binding molecules
|